Linzagolix will only be available for patients whose previous medical or surgical treatments have been unsuccessful.

A new at-home pill for endometriosis has been approved for use on the NHS.The once-a-day tablet, called linzagolix but also ...

A new daily tablet for endometriosis, called linzagolix (also known as Yselty), has been approved for use on the NHS and is ...

Clinical trials have shown linzagolix significantly reduces both menstrual pain and non-menstrual pelvic discomfort compared ...

Pfizer and Myovant have begun a late-stage trial of their potential uterine fibroid drug relugolix, as part of a contraceptive combination tablet. The FDA is already reviewing data from two ...

Myovant has chalked up a second approval for its flagship drug relugolix from the FDA, becoming the first once-daily oral drug in the US to treat heavy menstrual bleeding associated with uterine ...

Endometriosis is a chronic condition that occurs when cells similar to those in the lining of the womb grow in other parts of ...

Endometriosis is a painful condition that affects one in 10 women in the UK, and can have a big impact on women's lives. The ...

Linzagolix (Yselty) with hormonal add-back therapy will offer a new at-home treatment option for some women in England with ...

The pill, known as relugolix–estradiol–norethisterone (or relugolix combination therapy, branded as Ryeqo), is considered a breakthrough for the 1.5 million people in the UK living with ...

Relugolix–estradiol–norethisterone (relugolix combination therapy [CT]) can be used, within its marketing authorisation, as an option for treating symptoms of endometriosis in adults of reproductive ...